Radius Health, Inc. (NASDAQ:RDUS) Q4 2021 Earnings Conference Call February 24, 2022 8:30 AM ET Company Participants Ethan Holdaway - Head of Investor Relations Kelly Martin - President and Chief Executive Officer Steve Helwig - Principal Finance and Accounting Officer Bob Valentine - Business Intelligence and Digital, U.S. Commercial Chhaya Shah - Abaloparatide and Elacestrant Development and Operations Cole Ikkala - Business Operations, Neuroscience Group Peter Schwartzman - Corporate Finance Conference C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended November 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 000-22496 SCHNITZER STEEL INDUSTRIES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdic ...

Q3, 2021 Earnings November 8, 2021 Safe Harbor Any statements made in this presentation relating to future financial or business performance, guidance, conditions, plans, prospects, trends or strategies and other financial or business matters are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the continued commercialization of TYMLOS® (abaloparatide) injection and abaloparatide-SC ex-U.S., and the expected timing of our regula ...

Financial Data and Key Metrics Changes - TYMLOS net revenue for Q3 2021 was $56.8 million, a 13% increase from $50.4 million in Q3 2020, driven by increased unit volume and net price [19] - Total net revenue for Q3 2021 decreased by $21 million or 27% compared to Q3 2020, primarily due to a $27.4 million upfront licensing payment received in Q3 2020 related to the Menarini agreement [19] - Adjusted EBITDA for Q3 2021 was a loss of $10.9 million, compared to a positive $9.3 million in Q3 2020, reflecting a roughly $20 million swing due to the prior year's licensing revenue [20][21] - Year-to-date total net revenue decreased by $10.9 million, attributed to a $16.4 million decrease in licensing revenue, offset by a $5.5 million increase in TYMLOS net revenue [21][22] Business Line Data and Key Metrics Changes - The R&D expenses decreased by $4 million year-over-year due to the wind-down of Phase 3 trials, with expectations for further declines in 2022 [19] - Selling, general, and administrative expenses increased by $2 million due to one-time professional fees related to the implementation of a new ERP system [20] - TYMLOS new patient shipments grew by 10% year-over-year, indicating continued growth in patient cohorts [33] Market Data and Key Metrics Changes - The company adjusted its full-year 2021 TYMLOS revenue forecast to a range of $210 million to $220 million, down from a previous forecast of $240 million [23] - The company has a cash balance of $110 million as of September 30, 2021, exceeding expectations due to timing on an expected payment [24] Company Strategy and Development Direction - The company is focused on expanding the commercial footprint of TYMLOS and preparing for the introduction of a male indication for abaloparatide [10][11] - The partnership with Menarini for Elacestrant is a key focus, with plans for regulatory submissions in both the U.S. and Europe [11][27] - The company aims to manage its capital structure actively and is looking to utilize milestone payments to strengthen it [70] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the need to improve patient conversion rates and persistence on therapy as critical areas for growth [46][49] - The company is optimistic about the potential of Elacestrant and anticipates significant opportunities from its partnership with Menarini [95][96] - Management emphasized the importance of building a culture around exceptional teamwork and executing plans in a high-quality manner [13][14] Other Important Information - The company has completed enrollment in three pivotal studies and is awaiting readouts from the third [14] - The Elacestrant asset has a robust intellectual property portfolio, with multiple patents and potential regulatory exclusivity [25] Q&A Session Summary Question: Proportion of surgical osteoporosis cases receiving anabolic therapy - Management indicated that there are between 1.5 million and 3 million fracture PMO patients in the U.S., with a low overall market share for anabolics [40][41] Question: Factors driving changes in revenue guidance - Management cited patient conversion and persistence as key factors affecting revenue guidance, with ongoing efforts to improve these metrics [46][49] Question: Milestone payments related to Elacestrant - Management clarified that development milestones are related to monotherapy progress, while royalties and sales milestones are based on any utilization of the molecule [50] Question: Strategies to improve patient persistence - Management highlighted the importance of communication with healthcare providers and patients, as well as minimizing administrative hurdles to improve persistence [76][77] Question: Percentage of anabolic eligible patients not on therapy due to injection fear - Estimates suggest that 10% to 20% of patients eligible for anabolic therapy refuse due to needle phobia, representing a significant market opportunity [85][86] Question: Commercial strategy for abaloparatide transdermal system - Management indicated that the transdermal system will target needle-averse patients and will be positioned as an additive opportunity rather than a switching option [63][88]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended August 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 000-22496 SCHNITZER STEEL INDUSTRIES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of in ...

NASDAQ: SCHN Financial Results Fourth Quarter Fiscal 2021 October 21, 2021 Recycling Today for a Sustainable Tomorrow Safe Harbor Statements and information included in this presentation by Schnitzer Steel Industries, Inc. that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Except as noted herein or as the context ma ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended May 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 000-22496 SCHNITZER STEEL INDUSTRIES, INC. (503) 224-9900 (Registrant's telephone number, including area code) Securities regis ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended February 28, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 000-22496 SCHNITZER STEEL INDUSTRIES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended November 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to (503) 224-9900 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | Title of each c ...